TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22284296

Group type: EXPERIMENTAL
Intervention: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 3 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intermittent forces with a pause of 3 days before each reactivation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous forces (150 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intermittent forces
Number of subjects: 32
Study: 19573637

Group type: EXPERIMENTAL
Intervention: Acellular pertussis-containing quadrivalent pre-school booster (Td(5)ap-IPV; Repevax)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-cell pertussis (DTwP//Hib+oral poliomyelitis vaccine [OPV]) combination vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT(5)aP‐IPV‐Hib; Pediacel)
Number of subjects: 0
Study: 17877658

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15191447

Group type: EXPERIMENTAL
Intervention: Elective cervical cerclage
Number of subjects: 135

Group type: COMPARATOR
Intervention: Cervical surveillance program
Number of subjects: 135
Study: 12376442

Group type: EXPERIMENTAL
Intervention: Curtains impregnated with lambdacyhalothrin
Number of subjects: 2913

Group type: COMPARATOR
Intervention: Curtains without insecticide or no curtains (control group)
Number of subjects: 2913
Study: 9872701

Group type: EXPERIMENTAL
Intervention: Kaiser Permanente (KP) model of consultation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State model of consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State model of consultation (high-risk group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KP model of consultation (high-risk group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State model of consultation (low-risk group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KP model of consultation (low-risk group)
Number of subjects: 0
Study: 7644049

Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 10313312

Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy following mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 72237

Group type: EXPERIMENTAL
Intervention: Oral disopyramide (100 mg four times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 31374589

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) with optimal medical therapy (OMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) with surgical ventricular reconstruction (SVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical ventricular reconstruction (SVR) alone
Number of subjects: 0
Study: 28537418

Group type: EXPERIMENTAL
Intervention: Spinal manipulation of the thoracolumbar junction (Experimental Group, n=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham procedure (Control Group, n=23)
Number of subjects: 46
Study: 25662415

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care
Number of subjects: 400

Group type: COMPARATOR
Intervention: Orthopaedic care
Number of subjects: 400
Study: 23388527

Group type: EXPERIMENTAL
Intervention: EPO therapy (3 times per week for 6 months)
Number of subjects: 93
Study: 21767407

Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: naproxen 1000 mg
Number of subjects: 387

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 387
Study: 19567491

Group type: EXPERIMENTAL
Intervention: In-hospital treatment of OSA using auto-adjusting positive airway pressure along with standard treatment of ADHF
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard treatment for ADHF
Number of subjects: 46
Study: 17012419

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg single dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15268624

Group type: EXPERIMENTAL
Intervention: Twice-weekly humanised anti-IL-6R monoclonal antibody (MRA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Every-4-weeks regimen of MRA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11139984

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 0
Study: 9235470

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Intermittent noninvasive ventilation
Number of subjects: 2300
Study: 1604411

Group type: EXPERIMENTAL
Intervention: Single oral administration of CN-100 at a dose of 150 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single oral administration of CN-100 at a dose of 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of CN-100 at a daily dose of 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of CN-100
Number of subjects: 12
Study: 3728891

Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg i.v. prior to extubation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no physostigmine)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Physostigmine in patients younger than 60 years
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Physostigmine in sexagenarians (patients aged 60 years and older)
Number of subjects: 62
Study: 29240641

Group type: EXPERIMENTAL
Intervention: Low-dose insulin injections
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 91
Study: 26129928

Group type: EXPERIMENTAL
Intervention: Antioxidant group (500 mg of vitamin C and 117.5 mg vitamin E before and after training)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Antioxidant group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 23995581

Group type: EXPERIMENTAL
Intervention: tyrosine-phenylalanine depletion (TPD) beverage
Number of subjects: 16

Group type: COMPARATOR
Intervention: tyrosine-phenylalanine balanced (BAL) control beverage
Number of subjects: 16
Study: 22867101

Group type: EXPERIMENTAL
Intervention: Mixed-method cooling
Number of subjects: 8
Study: 20156396

Group type: EXPERIMENTAL
Intervention: Affective messages (N=31) - 1 SMS per day for 2 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Instrumental messages (N=30) - 1 SMS per day for 2 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined messages (N=31) - 1 SMS per day for 2 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (N=28) - 1 SMS per week
Number of subjects: 120
Study: 18564096

Group type: EXPERIMENTAL
Intervention: Erroneous examples with elaborated feedback
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Knowledge of correct result (KCR)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153
Study: 15858471

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Pimecrolimus cream
Number of subjects: 1065
Study: 12393113

Group type: COMPARATOR
Intervention: Intrathecal morphine 4.3 microg.kg(‐1) plus IV 0.9% saline (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV buprenorphine 1.3 microg.kg(‐1) plus intrathecal saline (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 4.3 microg.kg(‐1) plus IV buprenorphine 1.3 microg.kg(‐1) (Group 3)
Number of subjects: 45
Study: 10207203

Group type: EXPERIMENTAL
Intervention: Intravenous administration of basic fibroblast growth factor (bFGF) within hours after the onset of ischemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracisternal administration of basic fibroblast growth factor (bFGF) starting at one day after ischemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed administration of basic fibroblast growth factor (bFGF) as a recovery-promoting agent in subacute stroke
Number of subjects: 0
Study: 7553405

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Captopril 25 mg three times daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg daily (one-year open treatment)
Number of subjects: 75
Study: 2166758

Group type: EXPERIMENTAL
Intervention: Isolated EARs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Early responses preceding LARs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline levels in isolated responders
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline levels in dual responders
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Correlation of bronchoconstriction during EAR
Number of subjects: 18

Group type: COMPARATOR
Intervention: LAR
Number of subjects: 18
Study: 373489

Group type: EXPERIMENTAL
Intervention: Bupranolol (Ophtorenin) 0.05%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methazolamide (Neptazane) 50 mg p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methazolamide (Neptazane) 100 mg p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined application of Bupranolol and Methazolamide
Number of subjects: 0
Study: 7114587

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31146741

Group type: EXPERIMENTAL
Intervention: NS-21 cream applied three times per day during RT or CCRT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment applied three times per day during RT or CCRT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NS-21 cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30
Study: 29300287

Group type: EXPERIMENTAL
Intervention: Ceramide-infused ostomy skin barrier
Number of subjects: 153
Study: 27241125

Group type: EXPERIMENTAL
Intervention: Visceral Adipose Tissue (VAT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Subcutaneous Adipose Tissue (SAT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 97
Study: 24935272

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) at a dose of 5 μg/kg subcutaneously every 12 hours for 5 consecutive days (group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus G-CSF (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone (group B)
Number of subjects: 46
Study: 22343498

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 μM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pravastatin 50 μM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pravastatin 75 μM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pravastatin 5 μM
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 20849244

Group type: EXPERIMENTAL
Intervention: Epoetin beta (target 13.0-15.0 g/dL; Group 1)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Epoetin beta (target 10.5-11.5 g/dL; Group 2)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Epoetin beta (both groups)
Number of subjects: 291
Study: 16716541

Group type: EXPERIMENTAL
Intervention: Rooming-in with mothers after delivery
Number of subjects: 176

Group type: COMPARATOR
Intervention: Kept in the nursery after birth
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Swaddled babies with a 2-h separation period after birth
Number of subjects: 176

Group type: COMPARATOR
Intervention: Swaddled babies kept in the nursery with breast-milk supplements
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants
Number of subjects: 176

Group type: COMPARATOR
Intervention: Swaddled babies receiving supplements
Number of subjects: 176
Study: 16224157

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil monotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination therapy with ongoing lamivudine
Number of subjects: 46
Study: 11916811

Group type: EXPERIMENTAL
Intervention: Subgluteal approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Popliteal approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 60
Study: 9483448

Group type: EXPERIMENTAL
Intervention: Cimetidine 50 mg/kg administered intravenously just prior to IHCP (cimetidine group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IHCP without cimetidine (control group)
Number of subjects: 20
Study: 8536122

Group type: EXPERIMENTAL
Intervention: Radiography ordered for acute knee injuries
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Radiographic series ordered
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Physicians' prediction of fracture
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Physicians' comfort level with not ordering radiography
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics curve for physicians' prediction of fracture
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Likelihood ratios for physicians' prediction of fracture
Number of subjects: 3007
Study: 2237629

Group type: EXPERIMENTAL
Intervention: Posterior vertebral arthrodesis without instrumentation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Posterior vertebral arthrodesis with instrumentation (Harrington's technique)
Number of subjects: 48
Study: 710028

Group type: EXPERIMENTAL
Intervention: Naproxen alone (500 mg single oral dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naproxen with probenecid (500 mg 4 times a day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naproxen with probenecid (250 mg twice daily for 8 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naproxen with probenecid
Number of subjects: 6
Study: 31707266

Group type: EXPERIMENTAL
Intervention: Recommended Usual Care (R‐UC): 8 weeks of nicotine patch plus brief counseling
Number of subjects: 623

Group type: COMPARATOR
Intervention: Abstinence‐Optimized Treatment (A‐OT): 3 weeks of pre‐quit mini‐lozenges, 26 weeks of nicotine patch plus mini‐lozenges, 11 counseling contacts, and 7‐11 automated reminders
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 623
Study: 27642037

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention (EMI)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Intervention (FVI)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (Diet-as-usual)
Number of subjects: 171
Study: 25828193

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) exercise training, amplitude of 0.76 mm, frequency of 40Hz, peak acceleration of 23.9 m/s2, 5-week duration
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (statically mini-squatting position without WBV), 5-week duration
Number of subjects: 19
Study: 24158333

Group type: EXPERIMENTAL
Intervention: Platform switching (3.3-mm platform)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard implant (4-mm platform)
Number of subjects: 25
Study: 21088595

Group type: EXPERIMENTAL
Intervention: Head-down tilt position (15° head-down tilt)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Head-down tilt position
Number of subjects: 40
Study: 19875550

Group type: EXPERIMENTAL
Intervention: Enhanced lifestyle advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17520787

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 15470213

Group type: COMPARATOR
Intervention: Docetaxel every three weeks
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Weekly docetaxel
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 1006
Study: 12813832

Group type: EXPERIMENTAL
Intervention: Extended recruitment period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identified additional recruitment centres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced overall sample size
Number of subjects: 0
Study: 9048709

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (20 mg IV monthly) and methylprednisolone (1 g IV monthly)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Methylprednisolone alone
Number of subjects: 42
Study: 7508727

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 3525022

Group type: EXPERIMENTAL
Intervention: Oral terbutaline, 5 mg qid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline, 400 micrograms qid
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (identical tablets or metered-dose inhalers)
Number of subjects: 13
Study: 31286733

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (needles retained for 30 min, 3 times a day for 5 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment and care (Control group)
Number of subjects: 120
Study: 28190788

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg kg−1 hour−1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg kg−1 hour−1
Number of subjects: 24
Study: 26521582

Group type: EXPERIMENTAL
Intervention: Erlong Xizhu acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study: 23087258

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lupus health passport
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Quality of life and mental health improvements
Number of subjects: 29
Study: 21502549

Group type: EXPERIMENTAL
Intervention: Nadroparin (subcutaneous administration for 6 weeks: 2 weeks at therapeutic dose, 4 weeks at half therapeutic dose)
Number of subjects: 503

Group type: COMPARATOR
Intervention: No nadroparin (control group)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 503
Study: 18704414

Group type: EXPERIMENTAL
Intervention: Complete cementing (both under the baseplate and around the stem)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Horizontal cementing (only under the baseplate)
Number of subjects: 30
Study: 16504957

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (80 microg s.c. once a week for 24 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PEG‐IFN
Number of subjects: 22
Study: 15575830

Group type: EXPERIMENTAL
Intervention: Lacrimal occlusion with collagen plugs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Topical timolol (0.5%) without lacrimal occlusion
Number of subjects: 14
Study: 11144316

Group type: EXPERIMENTAL
Intervention: Maternal serum (MS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Umbilical cord (UC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amniotic fluid (AF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Infant serum leptin concentrations (N5)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 26
Study: 9072665

Group type: EXPERIMENTAL
Intervention: Immunomodulating drug of bacterial derivation
Number of subjects: 0
Study: 1476466

Group type: EXPERIMENTAL
Intervention: Quinine infusion regimen (8 mg of quinine base/kg of body weight over 1 h followed by 8 mg of base/kg over 7 h, then 8 mg/kg over 8 h 3 times daily for 3 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classical regimen (8 mg of base/kg over 8 h, 3 times daily for 3 days)
Number of subjects: 20
Study: 6439759

Group type: EXPERIMENTAL
Intervention: Oral digoxin, 0.5 mg daily, on days 10 through 22 of a menstrual cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous digoxin, 0.5 mg daily for days 7 through 21 of a menstrual cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30820517

Group type: EXPERIMENTAL
Intervention: Creatine-High (CR-H; 0.3 g/kg/day of creatine + 0.1 g/kg/day of maltodextrin)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Creatine-Moderate (CR-M; 0.1 g/kg/day of creatine + 0.3 g/kg/day of maltodextrin)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (PLA; 0.4 g/kg/day of maltodextrin)
Number of subjects: 33
Study: 29898437

Group type: EXPERIMENTAL
Intervention: verapamil (5 mg)
Number of subjects: 418

Group type: COMPARATOR
Intervention: heparin (5,000 IU)
Number of subjects: 418
Study: 27509603

Group type: COMPARATOR
Intervention: Routine detumescence (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupoint massage and mild moxibustion (observation group)
Number of subjects: 120
Study: 25271826

Group type: EXPERIMENTAL
Intervention: Headphones playing investigator-selected music
Number of subjects: 34

Group type: COMPARATOR
Intervention: Muted headphones
Number of subjects: 34
Study: 22922034

Group type: EXPERIMENTAL
Intervention: 22% carbamide peroxide (CP) with 3% potassium nitrate
Number of subjects: 21
Study: 20130407

Group type: EXPERIMENTAL
Intervention: Specific diet based on IgG antibodies against food antigens
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eosinophil-derived neurotoxin measurement
Number of subjects: 40
Study: 17919542

Group type: COMPARATOR
Intervention: Transdermal buprenorphine patch applied for 3 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine patch applied for 4 days
Number of subjects: 49